The pharmacokinetics profile of active pharmaceutical ingredients (APIs) in the solid pharmaceutical dosage forms is largely dependent on the solid-state characteristics of the chemicals to understand the physicochemical properties by particle size, size distribution, surface area, solubility, stability, porosity, thermal properties, etc. The formation of salts, solvates, and polymorphs are the conventional strategies for altering the solid characteristics of pharmaceutical compounds, but they have their own limitations. Cocrystallization approach was established as an alternative method for tuning the solubility, permeability, and processability of APIs by introducing another compatible molecule/s into the crystal structure without affecting its therapeutic efficacy to successfully develop the formulation with the desired pharmacokinetic profile. In the present review, we have grossly focused on cocrystallization, particularly at different stages of development, from design to production. Furthermore, we have also discussed regulatory guidelines for pharmaceutical industries and challenges associated with the design, development and production of pharmaceutical cocrystals with commercially available cocrystal-based products.

No abstract

Domperidone (DOM) (6-chloro-3-[1-[3-(2-oxo-3H-benzimidazole-1-yl) propyl] piperidin-4-yl]-1H-benzimidazole-2-one) is an antiemetic, galactagogue and gastrokinetic that works by blocking the dopamine receptor D2. Due to its low solubility, it finds difficult to cross the...

Focusing on reliable supramolecular synthons approach, novel molecular salts of the antihypertensive medication ketanserin (KTS) with benzoic acid derivatives (benzoic acid (BA), 2-hydoxybenzoic acid (2-HBA), 2,5-dihydroxybenzoic acid (2,5-DHBA)) are reported....

No abstract